PROCEPT BioRobotics Corporation (PRCT) Research
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Market snapshot
- Symbol
- PRCT
- Price
- $21.72
- Day change
- +3.87%
- Market cap
- $1.2B
- P/E ratio
- -11.98x
- 52-week range
- 19.35-62.17
- Sector
- Healthcare
- Industry
- Medical - Devices
- Next earnings
- in 2 months
- Analyst price target
- $32.00
Peer companies
Recent insider activity
- Desai Antal Rohit — A-Award (3315 shares) on 2026-06-09
- Desai Antal Rohit — A-Award (5853 shares) on 2026-06-09
- Dodrill Amy M. — A-Award (3315 shares) on 2026-06-09
- Dodrill Amy M. — A-Award (5853 shares) on 2026-06-09
- Garrett Mary — A-Award (3315 shares) on 2026-06-09
Open PROCEPT BioRobotics Corporation (PRCT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.